Lantern Pharma Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $11.5M | $16.1M | $11.9M | $8.6M | $7.6M |
| Operating expenses | $18.0M | $22.2M | $17.9M | $14.4M | $12.6M |
| Operating income | -$18.0M | -$22.2M | -$17.9M | -$14.4M | -$12.6M |
| Net income | -$17.1M | -$20.8M | -$16.0M | -$14.3M | -$12.4M |
| Balance Sheet | |||||
| Cash and equivalents | $4.4M | $7.5M | $21.9M | $37.2M | $51.5M |
| Current assets | $10.8M | $25.2M | $43.3M | $58.7M | $72.7M |
| Total assets | $11.0M | $25.6M | $43.6M | $58.8M | $74.0M |
| Current liabilities | $4.5M | $4.3M | $2.7M | $2.8M | $2.3M |
| Total liabilities | $4.5M | $4.4M | $2.7M | $2.8M | $2.4M |
| Stockholders' equity | $6.5M | $21.2M | $40.9M | $56.0M | $71.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$15.7M | -$17.8M | -$14.3M | -$12.8M | -$10.6M |
| Depreciation and amortization | $17,280 | $17,282 | $14,615 | $10,081 | $6,761 |
| Stock-based compensation | $651,000 | $652,000 | $1.0M | $1.2M | $961,545 |
| Capital expenditure | $1,715 | $12,595 | $18,734 | $27,844 | $15,499 |
| Free cash flow | -$15.7M | -$17.8M | -$14.4M | -$12.8M | -$10.6M |
| Share repurchases | — | — | $499,997 | $2.5M | $939,666 |
Shares outstanding 11.3M · Free float 56.9%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.